

DT09 Rec'd PCT/PTO 2 0 DEC 2004

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Application of:

BAILEY, Andrew, et al.

US Application No:

Not yet allocated

PCT Application No:

PCT/SE03/01079

PCT Filed:

June 23, 2003

For: Novel Purine-or Pyrrolol[2,3-d]Pyrimidine-2-Carbonitiles for Treating Diseases

Associated with Cysteine Protease Activity

Examiner: Not yet allocated Group Art Unit: Not yet allocated

Mail Stop PCT Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit herewith a list of patents and publications that Applicants believe may be material to the patentability of claims of the above-identified application and for which there may be a duty to disclose in accordance with 37 C.F.R. §1.56. Copies of the references, excluding US patents and publications, are also enclosed.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

This Information Disclosure Statement is being filed together with the filing under 35 U.S.C. § 371 of the national stage of an international application and hence no fee is required for consideration of the references. However, the Examiner is authorized to charge any fees that may be due to Deposit Account No. 26-0166.

Respectfully submitted,

Dated: December 20, 2004

Jianzhong Shen Agent for Applicants

Reg. No. 48,076

Telephone: 302/886-8854

10/518815

PTO/SB/08a (05-03)
Approved to hrough 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark O. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

001	inpicte ii Kilowii
Application Number	Not Yet Assigned
Filing Date DT09	Rec'd PCT/PTO 2 0 DEC 2004
First Named Inventor	Andrew Bailey
Art Unit	Not Known
Examiner Name	Not Known
Attorney Docket Number	100729-1P US

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (If known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US- 2002132810 A1	Sept. 19, 2002	Metcalf, et al.	
, ,		US-			
		US-			
-		US-			
		US-			delice.
		US-			
- 111		US-			
		US-			
		US-			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1		n Patent Document Code ³⁻ Number ⁴⁻ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
	B1		International Search Report				<u> </u>
	B2		International-Type Search Report				
	В3	wo	0055125 A2	Sept. 21, 2000	Axys Pharmaceuticals, Inc.		<u> </u>
	B4	wo	0232879 A1		Naeja Pharmaceuticals, Inc.		├
	R5	wo	03020721 A1	March 13, 2003	Novartis AG		

Examiner	Date Considered
Signature	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of considered. Include copy of this form with next communication to applicant unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. The Telephore Telepho

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use Lindugh 06/30/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

100729-1P US

Substitute for form 1449B/PTO Application Number DT09 Roc Filing Date INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor Andrew Bailey Art Unit Not Known (Use as many sheets as necessary) Examiner Name Not Known

a

Sheet

Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
	C1	STN International, CAPLUS accession no. 1991:484886, document no. 115:84886, NAIR, VASU et al., "Inhibition of mammaliandideoxyadenosines", & Biochemica et Biophysica Acta (1991), 1078(1), 121-3		
	C2	Database WPI, Week 200136, Derwent Publication Ltd., London, GB; Class B03, AN 2001-337719 & JP 2001 011037 A (KISSEI YAKUHIN KOGYO KK), 16 Jan. 2001 Abstract		
1\(\frac{1}{2}\).	-			
		·		

Date Examiner Considered Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.